Carcinoma, Renal Cell Clinical Trial
Official title:
A Retrospective Translational Study to Identify Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer
This research study aims to investigate changes inside kidney cancers (also known as Renal
Cell Carcinoma or RCC), and in normal kidney surrounding the tumour, when patients are
treated with systemic therapy.
Samples, radiological images and data from a previous trial (NeoSUN) will be analysed and/or
reanalysed, in accordance with the consent of NeoSUN participants.
This research study aims to investigate changes inside kidney cancers, and in normal kidney
surrounding the tumour, when patients are treated with systemic therapy. Systemic treatment
is widely used as routine treatment for patients who have kidney cancer that has spread to
other organs. It is also used sometimes before surgery to try to shrink kidney cancers to
make surgery easier and less risky. Recent research has shown that kidney cancers consist of
many different cells in addition to the cancer cells (including immune, structural and blood
vessel cells). However, doctors know very little about what changes systemic therapy causes
to cells other than cancer cells.
Researchers now think that these other cells may influence how the tumour cells behave during
cancer treatment and how well the cancer responds to treatment.
The NeoSUN clinical trial was run at Cambridge University Hospitals between 2006 and 2015.18
patients were treated with a TKI called sunitinib for 12 days before they had their kidney
surgically removed. MRI and CT scans were performed before and after the treatment. Samples
of tumour and normal kidney were also taken before and after treatment. All patients
consented to use of their tissue and data for future research projects. The investigators
would like to analyse the effects that sunitinib had on the tumour and other cells using
techniques called immunohistochemistry, immunofluorescence, and CyTOF. These mark the
different cells so they can easily be identified and the effects on each one analysed. The
investigators would also like to re-analyse the scans performed and use artificial
intelligence (AI) to see try to detect new trends. The information may help to guide which
drugs might be best used in future to treat kidney cancer more effectively whilst keeping
side effects low.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02248389 -
Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
|
Phase 1 | |
| Completed |
NCT03900364 -
a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
|
N/A | |
| Completed |
NCT00158782 -
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
|
Phase 1 | |
| Completed |
NCT03109015 -
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
|
Phase 2 | |
| Completed |
NCT00363194 -
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
|
Phase 1 | |
| Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
| Completed |
NCT00842790 -
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging
|
N/A | |
| Completed |
NCT00529802 -
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
|
Phase 2 | |
| Completed |
NCT00356460 -
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
|
Phase 1 | |
| Completed |
NCT00338884 -
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
|
Phase 2 | |
| Completed |
NCT00387764 -
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
|
Phase 3 | |
| Completed |
NCT00095186 -
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
| Completed |
NCT00079612 -
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04489771 -
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
|
Phase 2 | |
| Completed |
NCT00516672 -
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT05104905 -
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT03111901 -
Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 |